

Raquel DomÍnguez-Hernández

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7699928/publications.pdf>

Version: 2024-02-01

12
papers

145
citations

1306789

7
h-index

1199166

12
g-index

13
all docs

13
docs citations

13
times ranked

164
citing authors

#	ARTICLE	IF	CITATIONS
1	Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination. <i>Journal of Viral Hepatitis</i> , 2022, 29, 227-230.	1.0	10
2	Cost-effectiveness analysis of an active search to retrieve <sc>HCV</sc> patients lost to follow-up (<sc>RELINK</sc> strategy) and the impact of <sc>COVID</sc> 19. <i>Journal of Viral Hepatitis</i> , 2022, 29, 579-583.	1.0	7
3	Impact of the COVID-19 pandemic on HCV elimination in Spain. <i>Journal of Hepatology</i> , 2021, 74, 1246-1248.	1.8	22
4	Clinical and economic impact of an alert system in primary care for the detection of patients with chronic hepatitis C. <i>PLoS ONE</i> , 2021, 16, e0260608.	1.1	5
5	Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain. <i>Revista Española De Sanidad Penitenciaria</i> , 2020, 22, 66-74.	0.5	3
6	Is the universal population Hepatitis C virus screening a cost-effective strategy? A systematic review of the economic evidence. <i>Revista Espanola De Quimioterapia</i> , 2020, 33, 240-248.	0.5	5
7	La simplificación del proceso de diagnóstico de la hepatitis C crónica es una estrategia coste-efectiva. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 634-641.	0.3	12
8	Healthcare value of implementing hepatitis C screening in the adult general population in Spain. <i>PLoS ONE</i> , 2018, 13, e0208036.	1.1	22
9	Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. <i>Journal of Viral Hepatitis</i> , 2017, 24, 750-758.	1.0	10
10	Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2017, 40, 433-446.	0.0	7
11	Análisis coste-efectividad de dos estrategias de tratamiento para la hepatitis C crónica: antes y después del acceso a los agentes antivirales de acción directa en España. <i>Gastroenterología Y Hepatología</i> , 2017, 40, 433-446.	0.2	16
12	Value and innovation of direct-acting antivirals: long-term health outcomes of the strategic plan for the management of hepatitis C in Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 809-817.	0.1	19